SLC22A14 and breast carcinoma: Among the 6 DDM DEGs from JIB-04 treatment of MDA-MB-231 cells that showed opposite expression changes in TCGA analysis of breast cancers vs. normal breast tissues, 5 were upregulated (SLC22A14, ACVR1, FGF18, SVEP1, SERPIND1) and only 1 was downregulated (NAP1L3) in MDA-MB-231 cells upon JIB-04 treatment (Figure 7, bottom panel).